GE HealthCare and Mayo Clinic have announced a collaboration for the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) to explore personalized radioligand therapy options for advanced prostate cancer patients. This partnership arises from their 2023 Strategic Radiology Research Alliance, aimed at enhancing radiology practices and novel therapies. MI-BET seeks to evaluate imaging and biomarker data to customize treatment plans, potentially allowing for pauses in therapy based on individual disease responses. The initiative will use GE HealthCare’s StarGuide SPECT/CT technology and aims to broaden access to advanced theranostics, ultimately improving clinical decision-making and patient outcomes.
Thu, 09 Jul 2026 16:54:40 GMT | Imaging Technology News